Our drug discovery process seamlessly integrates cutting-edge technologies with expert medicinal chemistry and molecular design to create precisely tailored small molecule medicines. We employ advanced protein structure analysis, molecular simulations, machine learning-informed predictions, and comprehensive data analytics in a target-centric approach. The atomic-level insights provided by these tools fuel our ability to make precision molecules that deepen our understanding of target biology and define optimal pharmacological profiles for treating disease pathology. This integrated process enables us to expertly develop clinical candidates with precise attributes aimed at testing hypotheses in the clinic with unparalleled clarity.
Our rigorous yet nimble approach sets us apart in the industry. By leaning into our deep internal expertise and partnerships with academic, clinical, and industry leaders, we develop small molecule medicines with exceptional selectivity and potency—upholding our commitment to create life-changing treatments for patients. Our unique integration of expertise, combined with our ability to rapidly adapt to emerging scientific insights, has enabled us to design promising molecules with best-in-class potential, including those precisely designed for challenging targets such as TYK2 and HPK1, that have made advancements in the clinic.
This flexible, integrated approach isn’t just a philosophy—it’s a proven methodology that drives the development of groundbreaking therapies.
TARGET SELECTION
FOLLOWING THE SCIENCE TO BREAKTHROUGH TARGETS WITH THE POTENTIAL FOR A PROFOUND IMPACT ON
DISEASE
Nimbus is a “science first” biotech company. Our target selection process, one of our most crucial scientific endeavors, is driven by compelling evidence linking molecular targets to human disease pathology. We rigorously assess targets based on structural and computational tractability, unmet medical needs, and potential for blockbuster clinical candidates. Through comprehensive analysis across biology, chemistry, pharmacology, and translational medicine, Nimbus meticulously identifies targets integral to disease progression. We focus our drug discovery expertise where we can make a significant difference, ensuring every target we pursue has potential for broad patient impact. This approach underscores the critical importance of our target selection process in our overall mission.
DRUG DISCOVERY
DESIGNING EXQUISITELY POTENT
AND SELECTIVE SMALL
AND SELECTIVE SMALL
MOLECULES
OUR TOOLBOX INCLUDES
X-ray crystal-lography
Cryo-EM
Molecular docking
Physics-based simulation
Big data mining
PREDICTIVE MACHINE LEARNING TOOLS
TRANSLATIONAL MEDICINE
CLOSING THE LOOP
BETWEEN BENCH AND
BETWEEN BENCH AND
BEDSIDE
Our translational strategy is crafted to maximize the probability of success in clinical development. We integrate our deep understanding of biological pathways and pharmacology, derived from our Discovery efforts, with our internal technical expertise to ensure our trials target patients most likely to respond, demonstrate specific mechanism of action in the clinic, and achieve meaningful disease modification. This comprehensive approach forges a robust foundation for confident, data-driven decision-making, accelerating our breakthrough therapies to patients.
CLINICAL DEVELOPMENT
VALIDATING CLINICAL PROMISE FROM HYPOTHESIS TO
HOPE
Our clinical development approach is built on innovation, speed, and quality. We interrogate the science early to pinpoint the right patients and indications, always prioritizing patient needs. Through efficient trial designs and rigorous execution, we aim to provide clinical proof of concept with high confidence. By maintaining a patient-centric focus and leveraging an agile approach, we strive to accelerate the development of transformative therapies that address unmet medical needs. Ultimately, our goal is to pioneer best-in-class medicines that improve patients’ lives and offer physicians innovative therapeutic options, turning scientific hypotheses into medical breakthroughs.